Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-06-28
Study Completion Date
2012-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile lower cUTI and pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cUTI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
NCT01505634
Urinary Tract Infections
Pyelonephritis
COMPLETED
PHASE2
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
NCT01595438
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
COMPLETED
PHASE3
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
NCT00210990
Urinary Tract Infections
Pyelonephritis
COMPLETED
PHASE3
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
NCT00229021
Urinary Tract Infections
Pyelonephritis
COMPLETED
PHASE3
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
NCT03687255
Urinary Tract Infections
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Infections, Urinary Tract
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GSK2251052 750mg
q12h administered via IV infusion, plus saline placebo
Group Type
EXPERIMENTAL
GSK2251052
Intervention Type
DRUG
Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Placebo
Intervention Type
OTHER
saline placebo
GSK2251052 1500mg
q12h administered via IV infusion, plus saline placebo
Group Type
EXPERIMENTAL
GSK2251052
Intervention Type
DRUG
Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Placebo
Intervention Type
OTHER
saline placebo
imipenem-cilastatin
500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
Group Type
ACTIVE_COMPARATOR
imipenem-cilastatin
Intervention Type
DRUG
Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
Placebo
Intervention Type
OTHER
saline placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK2251052
Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Intervention Type
DRUG
imipenem-cilastatin
Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
Intervention Type
DRUG
Placebo
saline placebo
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Primaxin® (Manufacturer: Merck)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Adult subjects least 18 years of age.
N.B. Females of non-childbearing or childbearing potential may be enrolled. Females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate contraception for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:
* Abstinence; or,
* Oral Contraceptive, either combined estrogen/progesterone or progesterone alone, PLUS an additional barrier method \[ie, condom, occlusive cap (diaphragm or cervical/vault caps) or vaginal spermicidal agent (foam/gel/film/cream/suppository)\]; or,
* Injectable progesterone; or
* Implants of levonorgestrel; or,
* Estrogenic vaginal ring; or,
* Percutaneous contraceptive patches; or
* Intrauterine device (IUD) or intrauterine system (IUS) showing that failure rate is less than 1% in the IUD or IUS product label; or,
* Has a male partner who is sterilized (vasectomy with documentation of azoospermia).
* Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
* Females are considered to be of non-childbearing potential if they have documented tubal ligation or hysterectomy; or are postmenopausal, defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory\]
* Subject requires hospitalisation and has clinical signs and symptoms of lower cUTI or pyelonephritis (complicated or uncomplicated) as defined below, that requires parenteral treatment only with a treatment course of a minimum of 5 days and a maximum of 14 days:
* Lower cUTI - subjects must have documented fever defined as \>38°C oral, \>38.5°C tympanic or \>39°C rectal, within the last 24 hours exceptions would be:
* Afebrile subjects with lower cUTI who have a white blood cell count (WBC) ≥15,000 cells/mm3
* Afebrile subjects with a lower cUTI following requiring parenteral therapy due to a specific indication e.g. before and during an operative procedure, when oral antibiotics are not indicated or in cases where the cUTI is suspected to be due to a pathogen resistant to current oral antibiotics
* and at least two of the following UTI symptoms including dysuria, frequency, urgency or suprapubic pain, with the presence of a complicating factor:
* Male gender;
* Current bladder instrumentation or indwelling urinary catheter that has to be removed two days before the end of IV study drug administration;
* Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
* Urogenital surgery within 7 days preceding administration of the first dose of study drug;
* Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.
* Acute pyelonephritis (complicated or uncomplicated): subjects must have documented fever defined as \>38°C oral, \>38.5°C tympanic or \>39°C rectal, within the last 24 hours and flank pain or costovertebral angle tenderness (CVA). Complicating factors for pyelonephritis are the same as for complicated UTI.
* Subject has pyuria (white blood cell \[WBC\] count \> 10/µL (or \>5/high-power field \[HPF\] in a conventional urinalysis) in unspun clean-catch midstream urine (MSU) or catheter urine sample or \>= 10 WBC/HPF in spun MSU or catheter urine).
* Subject has Gram-negative organism(s) on direct examination of a Gram-stained specimen from unspun or spun MSU or catheter urine sample.
* Subject has provided a pre-therapy urine specimen obtained within 48 hours prior to the start of therapy, which when cultured has grown at least one and not more than two Gram-negative uropathogens at \>=10\^5 CFU/mL.
* A subject may be enrolled before the results of the pre-therapy urine culture is known, but the subject should be withdrawn from the study if the culture does not yield at least one but not more than two qualifying Gram-negative uropathogens at \>=10\^5 CFU/mL or if the culture yields Gram-positive uropathogens.
* A subject with lower cUTI or pyelonephritis (complicated or uncomplicated) who has failed a previous antibacterial treatment regimen is eligible provided a urine specimen is positive for one and not more than two bacterial Gram-negative uropathogens at \>=10\^5 CFU/mL. Subjects who are treatment failures due to imipenem-cilastatin should not be enrolled.
* QTcB or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block
N.B. Females of non-childbearing or childbearing potential may be enrolled. Females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate contraception for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:
* Abstinence; or,
* Oral Contraceptive, either combined estrogen/progesterone or progesterone alone, PLUS an additional barrier method \[ie, condom, occlusive cap (diaphragm or cervical/vault caps) or vaginal spermicidal agent (foam/gel/film/cream/suppository)\]; or,
* Injectable progesterone; or
* Implants of levonorgestrel; or,
* Estrogenic vaginal ring; or,
* Percutaneous contraceptive patches; or
* Intrauterine device (IUD) or intrauterine system (IUS) showing that failure rate is less than 1% in the IUD or IUS product label; or,
* Has a male partner who is sterilized (vasectomy with documentation of azoospermia).
* Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
* Females are considered to be of non-childbearing potential if they have documented tubal ligation or hysterectomy; or are postmenopausal, defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory\]
* Subject requires hospitalisation and has clinical signs and symptoms of lower cUTI or pyelonephritis (complicated or uncomplicated) as defined below, that requires parenteral treatment only with a treatment course of a minimum of 5 days and a maximum of 14 days:
* Lower cUTI - subjects must have documented fever defined as \>38°C oral, \>38.5°C tympanic or \>39°C rectal, within the last 24 hours exceptions would be:
* Afebrile subjects with lower cUTI who have a white blood cell count (WBC) ≥15,000 cells/mm3
* Afebrile subjects with a lower cUTI following requiring parenteral therapy due to a specific indication e.g. before and during an operative procedure, when oral antibiotics are not indicated or in cases where the cUTI is suspected to be due to a pathogen resistant to current oral antibiotics
* and at least two of the following UTI symptoms including dysuria, frequency, urgency or suprapubic pain, with the presence of a complicating factor:
* Male gender;
* Current bladder instrumentation or indwelling urinary catheter that has to be removed two days before the end of IV study drug administration;
* Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
* Urogenital surgery within 7 days preceding administration of the first dose of study drug;
* Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.
* Acute pyelonephritis (complicated or uncomplicated): subjects must have documented fever defined as \>38°C oral, \>38.5°C tympanic or \>39°C rectal, within the last 24 hours and flank pain or costovertebral angle tenderness (CVA). Complicating factors for pyelonephritis are the same as for complicated UTI.
* Subject has pyuria (white blood cell \[WBC\] count \> 10/µL (or \>5/high-power field \[HPF\] in a conventional urinalysis) in unspun clean-catch midstream urine (MSU) or catheter urine sample or \>= 10 WBC/HPF in spun MSU or catheter urine).
* Subject has Gram-negative organism(s) on direct examination of a Gram-stained specimen from unspun or spun MSU or catheter urine sample.
* Subject has provided a pre-therapy urine specimen obtained within 48 hours prior to the start of therapy, which when cultured has grown at least one and not more than two Gram-negative uropathogens at \>=10\^5 CFU/mL.
* A subject may be enrolled before the results of the pre-therapy urine culture is known, but the subject should be withdrawn from the study if the culture does not yield at least one but not more than two qualifying Gram-negative uropathogens at \>=10\^5 CFU/mL or if the culture yields Gram-positive uropathogens.
* A subject with lower cUTI or pyelonephritis (complicated or uncomplicated) who has failed a previous antibacterial treatment regimen is eligible provided a urine specimen is positive for one and not more than two bacterial Gram-negative uropathogens at \>=10\^5 CFU/mL. Subjects who are treatment failures due to imipenem-cilastatin should not be enrolled.
* QTcB or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block
Exclusion Criteria
Subjects meeting any of the following criteria must not be enrolled in the study:
* Concomitant infection requiring systemic antibacterial therapy other than study drugs at the time of randomisation.
* Subject is known to have one or more of the following:
* A urinary catheter that is not being removed during the study (or with an expectation that a catheter would be inserted during therapy with study drug and subsequently not removed during the study period; (intermittent straight catheterisation is acceptable)
* Complete permanent obstruction of the urinary tract;
* A permanent indwelling catheter or comparable instrumentation including nephrostomy that will not be removed during IV study drug administration
* Suspected or confirmed prostatitis
* Suspected or confirmed perinephric or intrarenal abscess
* A UTI suspected or confirmed to be fungal in origin (with \>= 10\^3 fungal CFU/mL)
* A UTI suspected or confirmed to be due to a Gram-positive uropathogen(s), with \>= 10\^5 Gram-positive organism CFU/mL;
* A UTI known at study entry to be caused by a pathogen(s) resistant to the study antimicrobial agent;
* Known ileal loops or vesico-ureteral reflux ;
* Polycystic kidney disease.
* Subject has an APACHE II score \>20
* Subject has known severe impairment of renal function including: a calculated creatinine clearance (CrCl) of less than 50 mL/min; requirement for peritoneal dialysis, haemodialysis, or haemofiltration; oliguria (less than 20 mL urine output per hour over 24 hours);
* Subject with an intractable lower cUTI requiring more than 14 Days IV treatment.
* Subjects with asymptomatic lower cUTI, such as subjects with spinal cord injury with lower cUTI who are not able to perceive symptoms due to their injury.
* Subject with lower cUTI or pyelonephritis (complicated and uncomplicated) who has received any amount of a potentially therapeutic antibiotic within the 96 h before providing the baseline urine culture specimen or prior to the start of the study.
* Subject has Gram-positive organism(s) on direct examination of a Gram-stained specimen of spun/unspun MSU or catheter urine.
* Subject is considered unlikely to survive the 4 6 week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).
* Subject has evidence of known or pre-existing severe hepatic disease (Child-Pugh score of B or C).
* Subject has a known baseline haemoglobin less than 10 g/dL ,haematocrit less than 30% and/or a known reticulocyte count of \>5% (i.e., reticulocytes \>5% of total RBC mass)
* Subject has known neutropenia or is anticipated to develop neutropenia during the course of the study (i.e., new chemotherapy subject), with absolute neutrophil count less than 1000 cells/mm3
* Subject has a known platelet count less than 75,000 cells /mm3 (subjects with platelet counts as low as 50,000 cells /mm3 are eligible if the reduction is historically stable).
* Subject has an immunocompromising illness; including known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplantation, hematological malignancy, and/or immunosuppressive therapy , including high-dose corticosteroids (e.g., greater than 40 mg prednisone or equivalent per day for greater than two weeks)
* Subject has participated in any investigational drug or device study within 30 days of study entry or within 5 half-lives, whichever is longer.
* Subject has previously received treatment with GSK2251052.
* Subject has a prior history of seizures or has a CNS abnormality predisposing them to seizures or has a lowered seizure threshold and/or is using concomitant medications with seizure potential.
* Subject requires probenicid or valproic acid medications.
* Subject has a history of moderate or severe hypersensitivity to beta-lactam antibiotics.
* Subject is pregnant or nursing
* Subject, in the opinion of the investigator may be significantly compromised by a potential drop in haemoglobin ≥2.5g/dl which is not related to the condition under study
* French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days
* Concomitant infection requiring systemic antibacterial therapy other than study drugs at the time of randomisation.
* Subject is known to have one or more of the following:
* A urinary catheter that is not being removed during the study (or with an expectation that a catheter would be inserted during therapy with study drug and subsequently not removed during the study period; (intermittent straight catheterisation is acceptable)
* Complete permanent obstruction of the urinary tract;
* A permanent indwelling catheter or comparable instrumentation including nephrostomy that will not be removed during IV study drug administration
* Suspected or confirmed prostatitis
* Suspected or confirmed perinephric or intrarenal abscess
* A UTI suspected or confirmed to be fungal in origin (with \>= 10\^3 fungal CFU/mL)
* A UTI suspected or confirmed to be due to a Gram-positive uropathogen(s), with \>= 10\^5 Gram-positive organism CFU/mL;
* A UTI known at study entry to be caused by a pathogen(s) resistant to the study antimicrobial agent;
* Known ileal loops or vesico-ureteral reflux ;
* Polycystic kidney disease.
* Subject has an APACHE II score \>20
* Subject has known severe impairment of renal function including: a calculated creatinine clearance (CrCl) of less than 50 mL/min; requirement for peritoneal dialysis, haemodialysis, or haemofiltration; oliguria (less than 20 mL urine output per hour over 24 hours);
* Subject with an intractable lower cUTI requiring more than 14 Days IV treatment.
* Subjects with asymptomatic lower cUTI, such as subjects with spinal cord injury with lower cUTI who are not able to perceive symptoms due to their injury.
* Subject with lower cUTI or pyelonephritis (complicated and uncomplicated) who has received any amount of a potentially therapeutic antibiotic within the 96 h before providing the baseline urine culture specimen or prior to the start of the study.
* Subject has Gram-positive organism(s) on direct examination of a Gram-stained specimen of spun/unspun MSU or catheter urine.
* Subject is considered unlikely to survive the 4 6 week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).
* Subject has evidence of known or pre-existing severe hepatic disease (Child-Pugh score of B or C).
* Subject has a known baseline haemoglobin less than 10 g/dL ,haematocrit less than 30% and/or a known reticulocyte count of \>5% (i.e., reticulocytes \>5% of total RBC mass)
* Subject has known neutropenia or is anticipated to develop neutropenia during the course of the study (i.e., new chemotherapy subject), with absolute neutrophil count less than 1000 cells/mm3
* Subject has a known platelet count less than 75,000 cells /mm3 (subjects with platelet counts as low as 50,000 cells /mm3 are eligible if the reduction is historically stable).
* Subject has an immunocompromising illness; including known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplantation, hematological malignancy, and/or immunosuppressive therapy , including high-dose corticosteroids (e.g., greater than 40 mg prednisone or equivalent per day for greater than two weeks)
* Subject has participated in any investigational drug or device study within 30 days of study entry or within 5 half-lives, whichever is longer.
* Subject has previously received treatment with GSK2251052.
* Subject has a prior history of seizures or has a CNS abnormality predisposing them to seizures or has a lowered seizure threshold and/or is using concomitant medications with seizure potential.
* Subject requires probenicid or valproic acid medications.
* Subject has a history of moderate or severe hypersensitivity to beta-lactam antibiotics.
* Subject is pregnant or nursing
* Subject, in the opinion of the investigator may be significantly compromised by a potential drop in haemoglobin ≥2.5g/dl which is not related to the condition under study
* French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Council Bluffs, Iowa, United States
Site Status
GSK Investigational Site
Topeka, Kansas, United States
Site Status
GSK Investigational Site
Corsicana, Texas, United States
Site Status
GSK Investigational Site
Chicoutimi, Quebec, Canada
Site Status
GSK Investigational Site
Sherbrooke, Quebec, Canada
Site Status
GSK Investigational Site
Suresnes, , France
Site Status
GSK Investigational Site
Toulouse, , France
Site Status
GSK Investigational Site
Athens, , Greece
Site Status
GSK Investigational Site
Chaïdári, , Greece
Site Status
GSK Investigational Site
Goudi, Athens, , Greece
Site Status
GSK Investigational Site
Thessaloniki, , Greece
Site Status
GSK Investigational Site
Irkutsk, , Russia
Site Status
GSK Investigational Site
Moscow, , Russia
Site Status
GSK Investigational Site
Rostov-on-Don, , Russia
Site Status
GSK Investigational Site
Smolensk, , Russia
Site Status
GSK Investigational Site
St'Petersburg, , Russia
Site Status
GSK Investigational Site
Alicante, , Spain
Site Status
GSK Investigational Site
Elche (Alicante), , Spain
Site Status
GSK Investigational Site
Getafe/Madrid, , Spain
Site Status
GSK Investigational Site
Granada, , Spain
Site Status
GSK Investigational Site
Madrid, , Spain
Site Status
GSK Investigational Site
Murcia, , Spain
Site Status
GSK Investigational Site
Pama de Mallorca, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
France
Greece
Russia
Spain
References
Explore related publications, articles, or registry entries linked to this study.
O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14. Epub 2014 Oct 27.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
114688
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286
COMPLETED
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
NCT02452047
COMPLETED
PHASE3
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
NCT02753946
COMPLETED
PHASE2/PHASE3
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
NCT03445195
COMPLETED
PHASE2
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
NCT00515034
COMPLETED
PHASE2
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
NCT05204368
NOT_YET_RECRUITING
PHASE3
A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.
NCT05554237
COMPLETED
PHASE1
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
NCT00965848
COMPLETED
PHASE4
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
NCT02728089
COMPLETED
PHASE3
A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects
NCT01262885
COMPLETED
PHASE1
Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
NCT03568942
COMPLETED
PHASE2
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
NCT03840148
COMPLETED
PHASE3
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
NCT03543436
COMPLETED
PHASE3
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
NCT03891433
SUSPENDED
PHASE4
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
NCT06522945
COMPLETED
PHASE1
A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study
NCT01702350
TERMINATED
PHASE1
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
NCT05905055
COMPLETED
PHASE3
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
NCT01763008
COMPLETED
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
NCT05584657
COMPLETED
PHASE3
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
NCT03174795
COMPLETED
PHASE1
A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
NCT04505683
COMPLETED
PHASE2/PHASE3
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
NCT00502801
COMPLETED
PHASE2
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
NCT02178254
COMPLETED
PHASE1
Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection
NCT05545137
COMPLETED
PHASE3